HD Focus

News Across the Globe

Skyhawk divulga resultados promissores do SKY-0515 e expande o estudo FALCON-HD para América Latina

ABH – Associação Brasil Huntington

Após indicadores seguros obtidos na fase 1 de estudos, o medicamento experimental entra em nova fase de testes para avaliar sua eficácia em centenas de pacientes em todo o mundo.

O post Skyhawk divulga resultados promissores do SKY-0515 e expande o estudo FALCON-HD para América Latina apareceu primeiro em ABH – Associação Brasil Huntington.

De uitdagingen van daten met de ziekte van Huntington

Nieuws - Vereniging van Huntington

Daten met de ziekte van Huntington (HD) heeft Tanita Allen geleerd hoe snel mensen eerlijkheid verwarren met een waarschuwingslabel, zo schrijft ze in haar nieuwe blog.

Ik dacht altijd dat vroeg in het proces de waarheid vertellen het meest respectvol was wat ik kon doen. En ik geloof nog steeds in eerlijkheid. Maar ik heb geleerd dat eerlijkheid me niet beschermt tegen misverstanden. Soms maakt het me juist een projectiescherm voor de angsten van anderen. Daten is al kwetsbaar. Met een chronische, progressieve ziekte wordt die kwetsbaarheid verdiept en soms vergroot.

The power of associationism present for the first time at the ENROLL-HD LANCOS meeting

Moving Forward

The power of associationism present for the first time at the ENROLL-HD LANCOS meeting – Written by Ruth Blanco, 15 February 2025 This February, we…

A Fault In The Supercomputer

HDBuzz

⏱️ 8 min read | Your brain is an advanced supercomputer. But in HD, a core processor starts to malfunction. A research group at UCLA has taken a close look to visualize the specific circuits going haywire – and how they look different in HD.

“From Regulator to Roadblock: How FDA Bureaucracy Stifles Innovation.” The US Senate Special Committee on Aging will convene a hearing with the FDA. Submit your statement!

Help 4 HD International

On Thursday, February 26, Chairman Rick Scott of the U.S. Senate Special Committee on Aging will convene a hearing entitled “From Regulator to Roadblock: How FDA Bureaucracy Stifles Innovation.” This hearing will explore how regulatory processes and evolving standards at the Food and Drug Administration (FDA) can unintentionally delay patient access to safe and effective therapies, particularly for individuals living with rare diseases. Members and expert witnesses will share the...

EHDN Clinical Research Congress 2026

Enroll

Harness Therapeutics – HRN001

Spoločnosť pre pomoc pri Huntingtonovej chorobe

17.2.2026 – pôvodná správa Látka je cielená na zvýšenie hladiny FAN1 proteínu určeného na opravu DNA. Liek je na báze ASO a zatiaľ je v predklinickej fáze. Klinické testovanie by chceli začať v roku 2027.  Originál článku tu. Ďalší článok o tomto lieku tu.

HARNESS Therapeutics: FAN1 Candidate selection Patient group Q&A

News - Huntington's Disease Society of America

Harness Therapeutics HRN001 Press Release

News - Huntington's Disease Society of America

RHS i Dagens Nyheter idag!

RHS Riksförbundet Huntingtons Sjukdom

Idag publicerades en artikel om Huntingtons sjukdom i Dagens Nyheter. Den beskriver hur samhället sviker familjer som är drabbade av Huntingtons sjukdom. Nedan finns ett utklipp av artikeln men hela artikeln finns att läsa på DN:s hemsida

Inlägget RHS i Dagens Nyheter idag! dök först upp på RHS Riksförbundet Huntingtons Sjukdom.

Light It Up 4 HD

Huntington's Australia

This May, for Huntington’s Disease (HD) Awareness Month, we’re proud to take part in the global #LightItUp4HD campaign....

Život s HCH

Spoločnosť pre pomoc pri Huntingtonovej chorobe

Aktualizácia 16.2.2026 Niečo o živote v riziku pre pochopenie.  Originál článku tu. Aktualizácia 16.8.2025 Niekedy si ľudia HCH neuvedomujú zmenu ktoré sa v ich stave dejú. Podľa najnovších zistení tento stav nemusí byť o tvrdohlavosti a odmietaní ale o fyzických zmenách na mozgu podľa MRI.  Originál článku tu. Aktualizácia 22.6.2025 Pri testovaní ľudí v skorom štádiu sa …

Život s HCH Čítajte viac »

Harness Therapeutics Nominates HRN001 Drug Candidate for HD and Launches Clinical Advisory Board

Research – International Huntington Association

Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntington’s Disease and Establishes Clinical Advisory Board Cambridge, UK, 16 February 2026: Harness Therapeutics (‘Harness’), a biotechnology company unlocking previously undruggable […]

Split Between Two Worlds: The Psychological Challenges for People at Risk of Huntington’s Disease

Enroll

⏱️ 7 min read | Living at risk for Huntington’s disease imposes a massive psychological burden. A small interview-style study of at risk 12 people dove into how these people cope day-to-day.

Disponibile in italiano la newsletter Enroll-HD – Edizione Dicembre 2025

corea di huntington -AICH ROMA ONLUS –

Siamo lieti di condividere  la newsletter di Enroll-HD – edizione dicembre 2025, ora disponibile anche in lingua italiana. Questa pubblicazione rappresenta un importante strumento di aggiornamento per pazienti, famiglie e caregiver, offrendo informazioni utili sulle attività del progetto Enroll-HD, sugli sviluppi della ricerca e sulle iniziative dedicate alla comunità coinvolta. L’obiettivo della traduzione è facilitare […]

L'articolo Disponibile in italiano la newsletter Enroll-HD – Edizione Dicembre 2025 sembra essere il primo su corea di huntington -AICH ROMA ONLUS -.

2025 issue Spanish

Enroll

2025 issue Italian

Enroll

2024 issue Italian

Enroll

7e maj – Välkommen till anhörigdag

RHS Riksförbundet Huntingtons Sjukdom

Varmt välkomna till anhörigdag den 7e maj i Göteborg och digitalt! Vi på RHS är medarrangörer tillsammans med Nationellt kompetenscentrum anhöriga med flera. För mer information vänligen besök deras hemsida https://anhoriga.se/kalender/anhorigdag/

Inlägget 7e maj – Välkommen till anhörigdag dök först upp på RHS Riksförbundet Huntingtons Sjukdom.

Putting it in print: oral drug branaplam lowered huntingtin, but safety concerns halted development

Enroll

⏱️10 min read | Results from the VIBRANT-HD trial are now published in a peer reviewed journal. This trial tested the oral drug, branaplam, which lowered HTT but had serious safety problems, ultimately halting the trial.